Please login to the form below

Not currently logged in

Michael Wyzga OncoMed board

He brings financial experience from Genzyme

Michael Wyzga OncoMedOncoMed has appointed industry veteran Michael Wyzga to the company's board of directors.

The cancer specialist is looking to make the most of Wyzga's years in the industry as it prepares to advance the development of its five drug candidates, with several new filings planned for 2014.

This experience includes serving as chief financial officer of the biotech Genzyme from 1998 to 2011, when the company was acquired by Sanofi in what was the second-largest acquisition in biotech history.

He is currently president and CEO of biopharma company Radius Health having joined the company in December 2011.

"As a CEO of an emerging biopharmaceuticals company and previous chief financial officer of one of the leading biotechnology companies in the world, Mike brings an excellent perspective to OncoMed's board following our successful initial public offering," said Paul Hastings, chairman and CEO of OncoMed.

In addition to its own prospects, OncoMed also has development deals with major pharma companies, including GlaxoSmithKline and Bayer.

23rd October 2013

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

Established in 2002, Star is a full service outsourcing and resourcing company that works with the best people and opportunities...

Latest intelligence

The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?